ClinicalTrials.gg
CompletedNCT02483078PRO140Updated Nov 3, 2022Results posted

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

A Phase 2/3 interventional study of PRO 140 and Placebo in HIV, sponsored by CytoDyn, Inc.. Completed at 36 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for 24 weeks respectively. Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two or more drug classes with limited treatment options).The options may be limited as a result of drug antiviral class cross-resistance or documented treatment intolerance.

Read the detailed description

PRO 140, in combination with other antiretroviral agents, is indicated for treatment experienced adult HIV-1 patients infected with CCR5-tropic virus. These patients must demonstrate evidence of HIV-1 replication despite ongoing antiretroviral therapy and have documented genotypic or phenotypic resistance to at least one ART drug within three drug classes (or within two or more drug classes with limited treatment option). The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs.

Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two drug classes with limited treatment option).

Enrollment will be stratified to have HIV-1 virus resistant to ART drugs within three drug classes or within two drug classes with limited treatment option.

The primary objective is to assess the efficacy, clinical safety and tolerability parameters of PRO 140 compared to placebo in reducing HIV-1 viral load during the 1-week double-blind treatment period. The secondary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with Optimized Background Therapy during the 24-week single-arm, open-label treatment period.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age ≥ 18 years
  2. Exclusive CCR5-tropic virus at Screening Visit
  3. Have a history of at least 3 months on current antiretroviral regimen
  4. Treatment-experienced -infected patients with documented genotypic or phenotypic resistance to at least one ART drug within three drug classes

    OR

    Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within two drug classes and have limited treatment options. The options may be limited as a result of drug antiretroviral class cross-resistance or documented treatment intolerance.

  5. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure.
  6. Plasma HIV-1 RNA ≥ 400 copies/mL at Screening Visit and documented detectable viral load (HIV-1 RNA >50 copies/ml) within the last 3 months prior to Screening Visit.
  7. Laboratory values at Screening of:

    • (ANC) ≥ 750/mm3
    • (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)
    • ≥ 75,000 /mm3
    • Serum (SGPT/ALT) \< 5 x (ULN)
    • Serum aspartate transaminase (SGOT/AST) \< 5 x ULN
    • (total) \< 2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
    • Creatinine ≤ 1.5 x ULN
  8. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator
  9. Both male and female patients and their partners of must agree to use 2 medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
  10. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written .

Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Documented CXCR4-tropic virus or Dual/Mixed tropic (R5X4) virus
  2. Patients with no viable treatment options (≤ 1 fully active drug)
  3. Any active infection or requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma) Note: Subjects infected by the virus or early stage virus will be eligible for the study.
  4. Laboratory test values of ≥ grade 3 DAIDS laboratory abnormality with the exception of the absolute criterion of \< 200/mm3
  5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  6. Unexplained fever or illness within 1 week prior to the first study dose
  7. Any vaccination within 2 weeks prior to the first study dose.
  8. Subjects weighing \< 35kg
  9. History of anaphylaxis
  10. History of Bleeding Disorder or patients on anti-coagulant therapy
  11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit or during the study
  12. Any known allergy or antibodies to the study drug or
  13. Treatment with any of the following:

    • Radiation or cytotoxic chemotherapy with 30 days prior to the Screening Visit or during the study
    • within 60 days prior to the Screening Visit or during the study
    • Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the Screening Visit or during the study
    • Oral or parenteral within 30 days prior to the Screening Visit or during the study. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:

      • Subjects on inhaled, nasal, or topical steroids will not be excluded.
  14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    PRO 140

    PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.

    Drug: PRO 140 · Drug: Optimized Background Regimen

  • Placebo comparator
    Placebo

    Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.

    Drug: Placebo · Drug: Optimized Background Regimen

Interventions

  • PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

    Also known as: PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5

  • DrugPlacebo
  • DrugOptimized Background Regimen

    Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.

    Also known as: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period

    The primary efficacy endpoint will be proportion of participants with a 0.5 log10 or greater reduction in HIV-1 RNA viral load from baseline at the end of the one week double-blind treatment period (Part 1).

    Time frame: From baseline visit to week 1 visit

Secondary outcomes

  1. Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option.

    Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. resistance to ART drugs within two drug class with limited treatment option (N = 24). This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups: 1. Participants with resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 24 participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Options

    Time frame: From baseline visit to week 1 visit

  2. Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes

    Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. Resistance to ART drugs within three drug classes (N = 28) This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups as follows: 1. Participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 28 participants with resistance to ART drugs within three drug classes

    Time frame: From baseline visit to week 1 visit

  3. Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

    The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded. The change from baseline in HIV-1 RNA levels was to be compared between the two (2) groups using Analysis of covariance (ANCOVA) with the stratification factor (i.e., Resistance to ART drugs at the time of randomization) included in the model.

    Time frame: From baseline visit to week 1 visit

  4. Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25 for All Patients and Within Each Stratum

    The number and percentages of subjects achieving HIV-1 RNA \< 400 copies/mL at Week 25, from the open label portion of the study, are presented

    Time frame: 25 weeks

  5. Percentage and Number of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25 for All Patients and Within Each Stratum

    The number and percentages of subjects achieving HIV-1 RNA \< 50 copies/mL at Week 25 are presented. This is from the 24 week open label portion of the of the trial.

    Time frame: 25 weeks

  6. Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum

    The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

    Time frame: 25 weeks

  7. Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

    The raw and change from baseline in CD4 cell count at the end of the 1-week double blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

    Time frame: From baseline visit to week 1 visit

  8. Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum

    The raw and change from baseline in CD4 cell count at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

    Time frame: 25 weeks

  9. Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

    The number and percentage of subjects with a ≥ 1log10 or greater reduction in HIV-1 RNA viral load from baseline was to be presented for the two (2) treatment groups. The analysis of change in viral load was done for subjects with ≥ 1.0 log10 reduction in HIV-1 RNA after the first week of treatment. The analysis is presented for the ITT population

    Time frame: From baseline visit to week 1 visit

Other outcomes

  1. Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions

    Assessments of subject-perceived injection site pain using the Pain Visual Analog Scale (VAS) were performed during each visit to the clinic for a study visit. Beginning at Treatment Visit 2 (T2), subjects were asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The subject marks on the line or by pointing to a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks The scale range is 0mm to 100 mm, with 0 mm = No Pain and 100 mm = Pain as bad as it could possibly be. In this measurement, a lower number corresponds to less perceived pain. T# = Visit Week#

    Time frame: 25 weeks

  2. Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

    The investigator was to carefully evaluate the comments of each subject and the response to treatment in order to judge the true nature and severity of the AE. The question of the relationship of AEs to study drug should have been determined by the investigator after thorough consideration of all available facts. To assess severity, the investigator was to use the DAIDS AE grading table for adverse events as well as any injection site reactions.

    Time frame: 25 weeks

  3. Frequency of Treatment-Emergent Serious Adverse Events

    The incidence of serious adverse events (SAEs) by relationship to the study treatment. In total, there were 16 SAEs reported for eight (8) subjects (15.4%, 8/52). Thirteen of the SAEs were determined to be Unrelated, three were determined to be Unlikely Related to study treatment.

    Time frame: 25 weeks

  4. Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.

    The number of study participants who had exclusive CCR5-tropic virus at study entry and subsequently developed Dual/Mixed (D/M)- and CXCR4-tropic virus at any time during study treatment while receiving PRO 140.

    Time frame: 25 weeks

07

Results

Posted Nov 3, 2022

Participant flow

Participants were enrolled from U.S. sites only. The first participant was enrolled on 21 October 2015 and the last subject completed the study on 25 July 2018.

Part 1 One-week Randomized
Participant flow — Part 1 One-week Randomized
MilestonePRO 140Placebo
Started2527
Completed2526
Not completed01
Withdrew: Lost to follow-up01
Part 2 Open Label Treatment Period
Participant flow — Part 2 Open Label Treatment Period
MilestonePRO 140Placebo
Started2526
Completed2521
Not completed05
Withdrew: Non-medical01
Withdrew: Withdrawal by subject01
Withdrew: Subject non compliant01
Withdrew: Lost to follow-up01
Withdrew: Adverse event01

Outcome measures

PrimaryProportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period

The primary efficacy endpoint will be proportion of participants with a 0.5 log10 or greater reduction in HIV-1 RNA viral load from baseline at the end of the one week double-blind treatment period (Part 1).

Time frame:
From baseline visit to week 1 visit
Reported as:
Number · Proportion of subjects
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period
Proportion of subjectsPRO 140Placebo
With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline.64.23
Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline.36.77
Statistical analysis
  • PRO 140 vs Placebo · Fisher Exact · p = .0032The Fisher's Exact test if the count in any cell was less than 5; otherwise Chi-Square test was to be used
SecondaryProportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option.

Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. resistance to ART drugs within two drug class with limited treatment option (N = 24). This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups: 1. Participants with resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 24 participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Options

Time frame:
From baseline visit to week 1 visit
Reported as:
Number · Proportion of participants
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option.
Proportion of participantsPRO 140Placebo
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option..7273.2308
Statistical analysis
  • PRO 140 vs Placebo · Fisher Exact · p = .0377
SecondaryProportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes

Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. Resistance to ART drugs within three drug classes (N = 28) This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups as follows: 1. Participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 28 participants with resistance to ART drugs within three drug classes

Time frame:
From baseline visit to week 1 visit
Reported as:
Number · Proportion of participants
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes
Proportion of participantsPRO 140Placebo
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes.5714.2308
Statistical analysis
  • PRO 140 vs Placebo · Fisher Exact · p = .1201
SecondaryMean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded. The change from baseline in HIV-1 RNA levels was to be compared between the two (2) groups using Analysis of covariance (ANCOVA) with the stratification factor (i.e., Resistance to ART drugs at the time of randomization) included in the model.

Time frame:
From baseline visit to week 1 visit
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
Log10 Copies/mLPRO 140Placebo
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum0.6 ± 0.450.1 ± 0.51
Statistical analysis
  • PRO 140 vs Placebo · ANCOVA · p = .0013
SecondaryPercentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25 for All Patients and Within Each Stratum

The number and percentages of subjects achieving HIV-1 RNA \< 400 copies/mL at Week 25, from the open label portion of the study, are presented

Time frame:
25 weeks
Reported as:
Count of participants · Participants
Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25 for All Patients and Within Each Stratum
ParticipantsPart 2 Open Label Portion
With HIV-1 RNA < 400 Copies/mL at Week 2537
Without HIV-1 RNA < 400 Copies/mL at Week 253
Missing12
SecondaryPercentage and Number of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25 for All Patients and Within Each Stratum

The number and percentages of subjects achieving HIV-1 RNA \< 50 copies/mL at Week 25 are presented. This is from the 24 week open label portion of the of the trial.

Time frame:
25 weeks
Reported as:
Count of participants · Participants
Percentage and Number of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25 for All Patients and Within Each Stratum
ParticipantsPart 2 Open Label Portion
With HIV-1 RNA < 50 Copies/mL at Week 2532
Without HIV-1 RNA < 50 Copies/mL at Week 258
Missing12
SecondaryMean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum

The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

Time frame:
25 weeks
Reported as:
Mean · Log10 copies/mL
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum
Log10 copies/mLPart 2 Open Label Portion
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum2.4 ± 1.42
SecondaryMean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

The raw and change from baseline in CD4 cell count at the end of the 1-week double blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

Time frame:
From baseline visit to week 1 visit
Reported as:
Mean · CD4 Cell Count
Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
CD4 Cell CountPRO 140Placebo
Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum41.1 ± 15425 ± 131
Statistical analysis
  • PRO 140 vs Placebo · ANCOVA · p = .7123
SecondaryMean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum

The raw and change from baseline in CD4 cell count at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.

Time frame:
25 weeks
Reported as:
Mean · CD4 Cell Count
Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum
CD4 Cell CountPart 2 Open Label Portion
Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum85.9 ± 175.2
SecondaryProportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum

The number and percentage of subjects with a ≥ 1log10 or greater reduction in HIV-1 RNA viral load from baseline was to be presented for the two (2) treatment groups. The analysis of change in viral load was done for subjects with ≥ 1.0 log10 reduction in HIV-1 RNA after the first week of treatment. The analysis is presented for the ITT population

Time frame:
From baseline visit to week 1 visit
Reported as:
Number · Proportion of participants
Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
Proportion of participantsPRO 140Placebo
Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum.2.0385
Statistical analysis
  • PRO 140 vs Placebo · Fisher Exact · p = .0993
Other pre-specifiedTolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions

Assessments of subject-perceived injection site pain using the Pain Visual Analog Scale (VAS) were performed during each visit to the clinic for a study visit. Beginning at Treatment Visit 2 (T2), subjects were asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The subject marks on the line or by pointing to a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks The scale range is 0mm to 100 mm, with 0 mm = No Pain and 100 mm = Pain as bad as it could possibly be. In this measurement, a lower number corresponds to less perceived pain. T# = Visit Week#

Time frame:
25 weeks
Reported as:
Mean · Units on a scale
Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions
Units on a scalePart 2 Open Label Portion
T2 (Week 2) Left Side Injection Site1.3 ± 8.5
T2 (Week 2) Right Side Injection Site1.0 ± 7.1
T3 (Week 3) Left Side Injection Site0.3 ± 1.5
T3 (Week 3) Right Side Injection Site0.2 ± 0.7
T4 (Week 4) Left Side Injection Site0.4 ± 1.7
T4 (Week 4) Right Side Injection Site0.3 ± 1.1
T5 (Week 5) Left Side Injection Site.7 ± 4
T5 (Week 5) Right Side Injection Site.1 ± .6
T6 (Week 6) Left Side Injection Site.8 ± 4.8
T6 (Week 6) Right Side Injection Site.3 ± 1.7
T7 (Week 7) Left Side Injection Site.2 ± .9
T7 (Week 7) Right Side Injection Site.3 ± 1.7
T8 (Week 8) Left Side Injection Site.3 ± 1.3
T8 (Week 8) Right Side Injection Site.4 ± 1.5
T9 (Week 9) Left Side Injection Site.2 ± .8
T9 (Week 9) Right Side Injection Site.2 ± .9
T10 (Week 10) Left Side Injection Site.3 ± 1.1
T10 (Week 10) Right Side Injection Site.3 ± 1.1
T11 (Week 11) Left Side Injection Site.3 ± 1.1
T11 (Week 11) Right Side Injection Site.2 ± 1
T12 (Week 12) Left Side Injection Site.9 ± 3
T12 (Week 12) Right Side Injection Site.8 ± 2.7
T13 (Week 13) Left Side Injection Site.1 ± .9
T13 (Week 13) Right Side Injection Site.1 ± .9
T14 (Week 14) Left Side Injection Site.4 ± 1.7
T14 (Week 14) Right Side Injection Site.4 ± 1.8
T15 (Week 15) Left Side Injection Site.1 ± .6
T15 (Week 15) Right Side Injection Site.2 ± .9
T16 (Week 16) Left Side Injection Site.4 ± 1.6
T16 (Week 16) Right Side Injection Site.2 ± .8
T17 (Week 17) Left Side Injection Site.1 ± .4
T17 (Week 17) Right Side Injection Site.1 ± .4
T18 (Week 18) Left Side Injection Site.2 ± 1.2
T18 (Week 18) Right Side Injection Site.3 ± 1.5
T19 (Week 19) Left Side Injection Site.3 ± 1.3
T19 (Week 19) Right Side Injection Site.2 ± 1.3
T20 (Week 20) Left Side Injection Site1.5 ± 8.9
T20 (Week 20) Right Side Injection Site1.1 ± 6
T21 (Week 21) Left Side Injection Site.8 ± 4.5
T21 (Week 21) Right Side Injection Site.4 ± 1.8
T22 (Week 22) Left Side Injection Site.2 ± .9
T22 (Week 22) Right Side Injection Site.2 ± .8
T23 (Week 23) Left Side Injection Site.3 ± 1.7
T23 (Week 23) Right Side Injection Site.2 ± .9
T24 (Week 24) Left Side Injection Site.2 ± 1.4
T24 (Week 24) Right Side Injection Site0 ± .2
T25 (Week 25) Left Side Injection Site.1 ± .6
T25 (Week 25) Right Side Injection Site0 ± .3
Other pre-specifiedFrequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

The investigator was to carefully evaluate the comments of each subject and the response to treatment in order to judge the true nature and severity of the AE. The question of the relationship of AEs to study drug should have been determined by the investigator after thorough consideration of all available facts. To assess severity, the investigator was to use the DAIDS AE grading table for adverse events as well as any injection site reactions.

Time frame:
25 weeks
Reported as:
Number · Number of Adverse Events
Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
Number of Adverse EventsPart 2 Open Label Portion
Moderate AEs40
Severe AEs15
Other pre-specifiedFrequency of Treatment-Emergent Serious Adverse Events

The incidence of serious adverse events (SAEs) by relationship to the study treatment. In total, there were 16 SAEs reported for eight (8) subjects (15.4%, 8/52). Thirteen of the SAEs were determined to be Unrelated, three were determined to be Unlikely Related to study treatment.

Time frame:
25 weeks
Reported as:
Number · Number of Serious Adverse Events
Frequency of Treatment-Emergent Serious Adverse Events
Number of Serious Adverse EventsPart 2 Open Label Portion
Unrelated13
Unlikely Related3
Other pre-specifiedEmergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.

The number of study participants who had exclusive CCR5-tropic virus at study entry and subsequently developed Dual/Mixed (D/M)- and CXCR4-tropic virus at any time during study treatment while receiving PRO 140.

Time frame:
25 weeks
Reported as:
Count of participants · Participants
Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.
ParticipantsPart 2 Open Label Portion
Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.2

Adverse events

Collected over 25 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pro 140 Weekly for 1 Week0/25 (0%)0/25 (0%)2/25 (8%)
Placebo Weekly for 1 Week0/27 (0%)0/27 (0%)2/27 (7.4%)
Part 2 PRO 140 Open Label for 24 Weeks0/52 (0%)8/52 (15.4%)34/52 (65.4%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPro 140 Weekly for 1 WeekPlacebo Weekly for 1 WeekPart 2 PRO 140 Open Label for 24 Weeks
PneumoniaInfections and infestations0/250/273/52
LymphadenopathyBlood and lymphatic system disorders0/250/271/52
DiarrhoeaGastrointestinal disorders0/250/271/52
PancreatitisGastrointestinal disorders0/250/271/52
Mycobacterium avium complex infectionInfections and infestations0/250/271/52
Septic shockInfections and infestations0/250/271/52
DehydrationMetabolism and nutrition disorders0/250/271/52
MalnutritionMetabolism and nutrition disorders0/250/271/52
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/271/52
ConvulsionNervous system disorders0/250/271/52
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPro 140 Weekly for 1 WeekPlacebo Weekly for 1 WeekPart 2 PRO 140 Open Label for 24 Weeks
DiarrhoeaGastrointestinal disorders0/250/276/52
Injection site haemorrhageGeneral disorders0/251/275/52
ArthralgiaMusculoskeletal and connective tissue disorders0/250/275/52
FatigueGeneral disorders1/250/273/52
Back painMusculoskeletal and connective tissue disorders0/250/273/52
PneumoniaInfections and infestations0/250/273/52
Upper respiratory tract infectionInfections and infestations0/250/273/52
RashSkin and subcutaneous tissue disorders0/250/273/52
NauseaGastrointestinal disorders1/250/272/52
Injection site painGeneral disorders0/251/272/52

Baseline characteristics

Intent-to-Treat: The Intent-to-Treat (ITT) population was defined as the set of subjects who were randomized and had received at least one (1) dose of leronlimab (PRO 140) or placebo. This population was to be used as the primary analysis population for the primary and secondary endpoints

Age, Continuous
Age, Continuous(years)PRO 140PlaceboTotal
Mean52.4 ± 8.652.4 ± 6.752.4 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)PRO 140PlaceboTotal
Female8614
Male172138
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRO 140PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American111324
White141327
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PRO 140PlaceboTotal
United States252752
Time since HIV Diagnosis
Time since HIV Diagnosis(years)PRO 140PlaceboTotal
Mean20.0 ± 9.520.8 ± 9.420.4 ± 9.4
Lowest CD4+ Cell Count
Lowest CD4+ Cell Count(Participants)PRO 140PlaceboTotal
<200 cells/mm^3101222
200-500 cells/mm^3131427
>500 cells/mm^3213
Number of ART Drug Exposure Prior to Enrollment
Number of ART Drug Exposure Prior to Enrollment(Number of ART Drugs prior to enrolment)PRO 140PlaceboTotal
Mean11.8 ± 4.89.6 ± 4.210.7 ± 4.6
Number of ART Drug with Documented Resistance
Number of ART Drug with Documented Resistance(Number of ART drugs with resistance)PRO 140PlaceboTotal
Mean9.4 ± 5.88.8 ± 3.39.1 ± 4.6
08

Study locations

36 sites
  • CD02 Investigational site
    Fountain Valley, California 92708, United States
  • CD02 Investigational site
    Long Beach, California 90813, United States
  • CD02 Investigational site
    Los Angeles, California 90008, United States
  • CD02 Investigational Site
    Los Angeles, California 90036, United States
  • CD02 Investigational site
    Palm Springs, California 92262, United States
  • CD02 Investigational Site
    San Francisco, California 94115, United States
  • CD02 Investigational site
    San Francisco, California 94118, United States
  • CD02 Investigational Site
    New Haven, Connecticut 06510, United States
  • CD02 Investigational site
    Norwalk, Connecticut 06850, United States
  • CD02 Investigational Site
    Washington, District of Columbia 20009, United States
  • CD02 Investigational site
    Washington, District of Columbia 20017, United States
  • CD02 Investigational Site
    Clearwater, Florida 33761, United States
  • CD02 Investigational site
    Fort Pierce, Florida 34982, United States
  • CD02 Investigational site
    Miami Beach, Florida 33139, United States
  • CD02 Investigational site
    Miami, Florida 20852, United States
  • CD02 Investigational site
    Miami, Florida 33136, United States
  • CD02 Investigational Site
    Miami, Florida 33169, United States
  • CD02 Investigational site
    Orlando, Florida 32803, United States
  • CD02 Investigational site
    West Palm Beach, Florida 33401, United States
  • CD02 Investigational site
    Chicago, Illinois 60613, United States
  • CD02 Investigational site
    Wichita, Kansas 67214, United States
  • E Study Site
    Las Vegas, Nevada 89109, United States
  • CD02 Investigational site
    New York, New York 10001, United States
  • CD02 Investigational site
    New York, New York 10011, United States
  • CD02 Investigational site
    Syracuse, New York 13210, United States
  • CD02 Investigational site
    Charlotte, North Carolina 28226, United States
  • CD02 Investigational site
    Cincinnati, Ohio 45267, United States
  • CD02 Investigational Site
    Austin, Texas 78705, United States
  • CD02 Investigational Site
    Bellaire, Texas 77301, United States
  • CD02 Investigational site
    Dallas, Texas 75231, United States
  • CD02 Investigational Site
    Houston, Texas 77004, United States
  • CD02 Investigational site
    Houston, Texas 77098, United States
  • CD02 Investigational Site
    Annandale, Virginia 22003, United States
  • CD02 Investigational Site
    Spokane, Washington 99202, United States
  • CD02 Investigational site
    Ponce, 00716-2347, Puerto Rico
  • CD02 Investigational site
    San Juan, 00909, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Feb 2018, 28 months.

Results were first posted in Nov 2022, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2015
First posted
Jun 26, 2015
StartActual
Oct 2015
Primary completionActual
Feb 2018
CompletionActual
Jul 2018
Results first posted
Nov 3, 2022
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02483078
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Oct 2015
Primary completion
Feb 2018
Completion
Jul 2018
Results posted
Nov 3, 2022
Last update
Nov 3, 2022

Study contacts

Edwin DeJesus, MD, FACP,
principal investigator · Orlando Immunology Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion